alexa Extracellular Matrix Molecules as Targets for Melanoma Therapy | OMICS International
ISSN: 2161-1459
Journal of Clinical & Experimental Pharmacology

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Extracellular Matrix Molecules as Targets for Melanoma Therapy

Gerardo Botti*, Margherita Cerrone, Annamaria Anniciello, Rossella De Cecio, Paolo Ascierto, and Monica Cantile

National Cancer Institute-Fondazione Pascale, Naples, Italy

*Corresponding Author:
Gerardo Botti
Department of Pathology
National Cancer Institute-Fondazione Pascale
Naples, Italy
Tel: +39 081 5903766
Fax: +39 081 5903718
E-mail: [email protected]

Received date: November 21, 2012; Accepted date: November 23, 2012; Published date: November 26, 2012

Citation: Botti G, Cerrone M, Anniciello A, De Cecio R, Ascierto P, et al. (2012) Extracellular Matrix Molecules as Targets for Melanoma Therapy. Clin Exp Pharmacol 2:e118. doi: 10.4172/2161-1459.1000e118

Copyright: © 2012 Botti G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Clinical & Experimental Pharmacology


The incidence of melanoma is gradually growing around the world, with particular increase among young individuals. The out-ofcontrol cell growth and the loss of cellular homeostasis play a key role in the genesis and progression of the tumor. At junction level these mechanisms control the proliferation, differentiation and apoptosis of melanocytes. In particular, interactions between transformed cells and transformed cell with extracellular matrix are crucial for melanoma progression. Molecules of the extracellular matrix in tumor microenvironment are responsible for tumor progression. Therefore, in order to establish specific target therapies, it is extremely important to set up molecular models which inhibit their activity.

Several studies have proved, for various tumor typologies, the possibility either to inhibit or interfere with the function of these molecules, both in vitro and in vivo. The inhibition can take place at gene transcription level, using specific siRNA, as well as at protein level using specific antibodies against ECM proteins [1-7].

Silencing, employing specific siRNA, causes a reduction in cell proliferation, colony formation and invasiveness of tumor cells in vitro as demonstrated by Dong et al. [8] and Shen et al. [9] on metallo proteinases investigations. Besides in vitro studies carried out on cell models of melanoma have shown that the down-regulation by siRNA technique of MMP13 strongly enhanced pigmentation of melanocytes as well as a decreasing in cell proliferation [10].

MMP-2 silencing, through adenovirus-mediated and siRNA techniques in spinal metastatic melanoma model, significantly inhibits tumor growth and results in a complete retention of neurological function in animals [11].

Several molecules have been considered capable of inhibiting MMPs catalytic activity, especially pseudopeptides and non-peptidic molecules, which selectively bind themselves to zinc-bing site of these proteins. Batimostat, barimostat, AG3344 and bay-219566 are the most used molecules at present [12].

Many integrin-inhibitors have also been set up. They have a strong capacity of inhibiting the progression of neoplastic cells as shown by studies on animal models. In particular, Cyclic RGD peptides have been synthetized, which selectively inhibit alpha v integrins [13,14]. Synthetic peptides against alpha5beta1 and alphavbeta3 integrins are now days employed in pre-clinical studies [15-17]. “Disintegrins” represent another category of integrin inhibitors. They are small nonenzymatic proteins with the capacity of interacting with many cell types, including melanoma cells. Salmosin, Jararhagin, Eristostatin, Contortrostatin and Obtustatin are the most studied and used “disintegrins” [18-22].

Anti-integrin antibodies have also been obtained (targeting alpha vs. integrins in particular): in mice model, Vitaxin and CNT095 strongly inhibit the growth of melanoma tumors [23].

The employment of RNA interference (siRNA), blocking Osteopontin (OPN) expression in melanoma cells, reduces cells number and invasiveness [24], whereas in other tumors, the employment of siRNA against OPN transcript causes a consistent suppression of tumorigenicity in vitro [25]. Beside, blocking of OPN expression can down-regulate other ECM molecules, specifically some metallo proteinases [26].

In recent years, several molecules have been identified as inhibitors of OPN, in particular Agelastatin A, an alkaloid with high anti-tumor efficacy [27]. Humanized monoclonal antibodies blocking OPN have been lately targeted: ASK 8007, is very efficacious in patients with rheumatoid arthritis [28] and anti-human OPN antibody 1A12 is used in breast cancer treatment [29].

Regarding SPARC (Osteonectin) silencing, it has been shown that anti-sense expression vector in melanoma cells is capable of reducing the invasive and adhesive capacity of tumor cells [30]. Moreover, siRNA blocking SPARC expression in cell and animals models of melanoma, inhibits cell growth with G (1) arrest induction [31]. In uveal melanoma too, OPN silencing is capable of reducing tumor cells proliferation [32].

Small peptides have been recently synthesized. Their molecular structure is very simple, capable of binding different SPARC protein domains, blocking angiogenesis and inhibiting tumor growth as shown in animal models [33,34].

The effects of both siRNA [35] and monoclonal antibodies against different domains of Tenascin C protein has also been investigated [36].

Finally, CCN3 protein expression is in reverse correlation to neoplastic progression of melanoma. Many experiments on both induction and silencing of CCN3 have been carried out and the results have shown a subsequent alteration of adhesion capacity to laminin and vitronectin [37].

It is then feasible to assume that the improvement and progression of therapeutic approaches for melanoma could be achieved by the integration of specific therapies against ECM molecules combined with immunotherapy.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 4th International Conference on Drug Discovery, Designing and Development
    June 27-28, 2018 Vancouver, Canada
  • 18th World Pharma Congress
    October 18-19, 2018 Warsaw, Poland

Article Usage

  • Total views: 11769
  • [From(publication date):
    December-2012 - Jun 21, 2018]
  • Breakdown by view type
  • HTML page views : 8000
  • PDF downloads : 3769

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7